Piper Sandler & Co’s Fate Therapeutics FATE Stock Holding History

Piper Sandler & Co’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-6,217	Closed	-$61K	–	16
2018 Q1	$61K	Buy	+6,217	New	+$59.6K	0.12%	10

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Piper Sandler & Co's FATE Position: Q2 2018 in Review

Piper Sandler & Co sold out of Fate Therapeutics (FATE) in Q2 2018, closing a stake of 6,217 shares — an estimated $61K sold.

Piper Sandler & Co first reported a position in FATE in Q1 2018 and held it in 1 quarter. The position peaked at $61K in Q1 2018. 103 funds tracked by Wall St. Rank hold FATE as of Q2 2018.

Piper Sandler & Co reported no remaining Fate Therapeutics position as of Q2 2018 after selling out during the quarter.
Piper Sandler & Co sold 6,217 Fate Therapeutics shares in Q2 2018, an estimated $61K.
Piper Sandler & Co first reported a position in Fate Therapeutics in Q1 2018 and held it in 1 quarter.
Piper Sandler & Co's Fate Therapeutics position peaked at $61K in Q1 2018.
103 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2018.

Based on Piper Sandler & Co's 13F filing for Q2 2018, filed 13 Aug 2018.